A Phase 2, Open Label, Multicenter, Single-stage Study to Evaluate the Efficacy of Isatuximab Plus Pomalidomide and Dexamethasone (IPd), in Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy
Latest Information Update: 03 Oct 2024
At a glance
- Drugs Dexamethasone (Primary) ; Isatuximab (Primary) ; Pomalidomide (Primary)
- Indications Amyloid light-chain amyloidosis
- Focus Therapeutic Use
- Acronyms IsAMYP
- 05 Mar 2024 Planned End Date changed from 1 May 2025 to 1 Mar 2026.
- 05 Mar 2024 Planned primary completion date changed from 1 May 2025 to 1 Mar 2026.
- 28 Feb 2023 Planned End Date changed from 1 Nov 2024 to 1 May 2025.